SHANGHAI – Making a strong move to enter China's cardiovascular (CDV) market, Shanghai-based Eddingpharm Co. Ltd. inked a deal with Amarin Corp. plc, of Dublin, to bring Vascepa to Greater China. Amarin will receive a nonrefundable $15 million up-front payment, while the total deal is valued at $169 million in milestones and tiered sales royalties.